Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Missouri
Clinical trial register · United States · industry-sponsored

Clinical Trials in Missouri, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 5290 Florida 4430 Illinois 2481 Georgia 2368 Arizona 2238
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca45 Merck Sharp & Dohme LLC36 Pfizer20 AbbVie20 Novartis Pharmaceuticals18
State
California5290 Florida4430 Illinois2481 Georgia2368 Arizona2238
All 51 states
Target enrolment
to

Trials with a site in Missouri

990 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
NCT07818759Sanfilippo Syndrome (MPS III)
NeuroGT
Phase 1/2
9
Missouri
2027-01-18
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
California, Florida, Maryland, Missouri, New Jersey, New York, Ohio, Texas
2026-10-15
Not yet open
A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A
NCT07830732Haemophilia A
Novo Nordisk A/S
Phase 3
84
Iowa, Louisiana, Minnesota, Missouri, North Carolina, Oklahoma, Pennsylvania, Texas
2026-10-09
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
NCT07285798Irritability Associated With Autism Spectrum Disorder
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-10-02
Not yet open
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
NCT07845500Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
DrugsBerobenatide·Tirzepatide·Semaglutide
Pfizer
Phase 3
660
Alabama, Florida, Kentucky, Michigan, Missouri, Montana, North Carolina, Ohio
2026-10-01
Not yet open
NANOVAE to Treat Knee Osteoarthritis (KOA)
NCT06606561Knee Osteoarthritis
Nova Vita Laboratory
Phase 1/2
24
Missouri
2026-10-01
Not yet open
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
NCT07429838Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
eGenesis, INC
Phase 1/2
20
Missouri, Wisconsin
2026-10
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
California, Colorado, Florida, Hawaii, Illinois, Maryland, Minnesota, Missouri
2026-09-30
Recruiting
A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections
NCT07379684Surgical Wound Infection, Traumatic Wound Infection
Macro Biologics, Inc.
Phase 1
44
California, Idaho, Maryland, Missouri, Ohio
2026-09-30
Not yet open
Evaluation of the F&P Licorice Mask, US, 2026
NCT07826429Chronic Respiratory Conditions, Obstructive Sleep Apnea (OSA)
Fisher and Paykel Healthcare
Not applicable
45
Missouri
2026-09-28
Recruiting
A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414Overweight, Obesity
DrugsZenagamtide·Semaglutide
Novo Nordisk A/S
Phase 3
650
California, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana, Missouri
2026-09-22
Recruiting
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
NCT07819435Androgenetic Alopecia
Pelage Pharmaceuticals, Inc.
Phase 2/3
600
Arkansas, California, Florida, Georgia, Indiana, Louisiana, Minnesota, Missouri
2026-09-21
Not yet open
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
NCT07371429Urinary Tract Infections
DrugGepotidacin
GlaxoSmithKline
Phase 1
25
California, Louisiana, Maryland, Missouri
2026-09-18
Recruiting
Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)
NCT07587021Primary Hyperoxaluria Type 1, PH1
YolTech Therapeutics Co., Ltd
Phase 2
36
Alabama, Colorado, Missouri, Pennsylvania
2026-09-16
Recruiting
ATR 1072 in Participants With PRKAG2 Syndrome
NCT07738107Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic, Wolff-Parkinson-White Syndrome
Atrium Therapeutics
Phase 1/2
37
Missouri
2026-09-14
Recruiting
Comparison of ACUVUE® OASYS MAX 1-Day Multifocal and DAILIES® AquaComfort Plus® Multifocal
NCT07788521Visual Acuity
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
DrugElritercept
Takeda
Phase 3
324
Arizona, California, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Montana
2026-09-10
Recruiting
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
NCT07192471T-cell NHL (PTCL or CTCL)
Kyowa Kirin, Inc.
Phase 1
72
California, Florida, Georgia, Iowa, Massachusetts, Missouri, New Jersey, New York
2026-09-02
Not yet open
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
Abiomed Inc.
Not applicable
250
Florida, Indiana, Minnesota, Missouri, New Jersey, North Carolina, Pennsylvania, Tennessee
2026-09-01
Recruiting
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
NCT07759154Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
80
Florida, Louisiana, Massachusetts, Missouri, Nevada, New Jersey, New York, Ohio
2026-09-01
Recruiting
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
NCT07645248Asthma
GlaxoSmithKline
Phase 3
110
Florida, Kentucky, Missouri, Nevada, Oregon, South Carolina, Texas
2026-09-01
Recruiting
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
NCT07588672Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Polyrizon Ltd.
Not applicable
120
Illinois, Missouri, New Jersey, Texas
2026-09-01
Not yet open
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
NCT07832136Thyroid Eye Disease
Viridian Therapeutics, Inc.
Phase 4
30
California, Florida, Massachusetts, Michigan, Missouri, New Jersey, Texas
2026-09
Recruiting
An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
NCT07426419Dilated Cardiomyopathy (DCM), BAG3 Mutation Associated Dilated Cardiomyopathy
Affinia Therapeutics
Phase 1/2
22
Florida, Missouri, Texas
2026-09
Recruiting
A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07743671Hereditary Hemorrhagic Telangiectasia
DrugEngasertib
Vaderis Therapeutics AG
Phase 3
240
Illinois, Indiana, Minnesota, Missouri
2026-09
Recruiting
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
NCT07123779Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
DrugHS235
35Pharma Inc
Phase 1/2
126
Missouri, South Carolina
2026-09
Recruiting
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
NCT07569926Prostate Cancer
DrugPiflufolastat
Blue Earth Diagnostics
Phase 4
142
California, Georgia, Massachusetts, Missouri, Oregon, Texas
2026-08-31
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
DrugPALI-2108
Palisade Bio
Phase 2
204
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2026-08-28
Recruiting
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
NCT07766655Smoking Cessation
DrugsDextromethorphan-bupropion·Bupropion
Axsome Therapeutics, Inc.
Phase 3
705
Arkansas, California, Florida, Georgia, Illinois, Indiana, Missouri, New York
2026-08-27
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
NCT07729462Preventive Treatment of Migraine
DrugRimegepant
Pfizer
Phase 3
400
Arizona, California, Florida, Indiana, Massachusetts, Michigan, Missouri, Nebraska
2026-08-26
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
DrugLenbelintide
AstraZeneca
Phase 3
500
California, Florida, Georgia, Illinois, Maryland, Missouri, Nevada, New Jersey
2026-08-24
Recruiting
Real-World Treatment of Extracranial Carotid Artery Disease With the ENROUTE™ Transcarotid Neuroprotection System
NCT07455747Extracranial Carotid Artery Disease, TCAR, Transcarotid Artery Revascularization
Boston Scientific Corporation
Observational
5,000
Missouri
2026-08-19
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Florida, Georgia, Michigan, Missouri, North Carolina, Ohio, South Carolina, Texas
2026-08-13
Recruiting
A Study of V132 in Healthy Older Participants (V132-001)
NCT07712575Healthy
DrugsCapvaxive·Prevnar 20
Merck Sharp & Dohme LLC
Phase 1
280
California, Florida, Missouri, Nebraska, Ohio, Rhode Island, Texas
2026-08-12
Recruiting
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841Overweight, Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
450
Alabama, California, Florida, Hawaii, Kentucky, Missouri, Nevada, Oregon
2026-08-12
Recruiting
A Study of LY3971297 in Participants With Heart Failure
NCT07547540Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Eli Lilly and Company
Phase 1
90
Michigan, Missouri, North Carolina, Texas
2026-08-11
Recruiting
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
NCT07702032Left-sided Colorectal Cancer
DrugsPetosemtamab·MFOLFOX6·Folfiri·Cetuximab
Genmab
Phase 3
960
Georgia, Indiana, Missouri, Washington
2026-08-11
Not yet open
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
NCT07742644Measles, Mumps, Rubella, Varicella (Chickenpox)
GlaxoSmithKline
Phase 3
1,860
Arkansas, California, Florida, Idaho, Illinois, Kentucky, Louisiana, Missouri
2026-08-11
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07711418Moderate-to-Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 3
510
Alabama, California, Florida, Georgia, Louisiana, Missouri, Nevada, New Jersey
2026-08-07
Recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
NCT07494045CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
OPKO Health, Inc.
Phase 2
40
Missouri, Ohio, Pennsylvania, South Carolina, Wisconsin
2026-08-05
Recruiting
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
DrugsTpo-Ra·Avatrombopag·Romiplostim·Eltrombopag
Novartis Pharmaceuticals
Phase 2
164
Arkansas, Connecticut, Florida, Illinois, Louisiana, Minnesota, Missouri, Montana
2026-08-04
Recruiting
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
NCT07752979Obesity, Overweight
DrugABBV-295
AbbVie
Phase 2
360
Alabama, Arizona, California, Florida, Idaho, Illinois, Kentucky, Missouri
2026-08-04
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Alabama, California, Florida, Georgia, Idaho, Illinois, Kansas, Missouri
2026-07-31
Recruiting
A Study Evaluating a New Radiation Treatment Workflow (NGDS)
NCT07824583Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers
Varian, a Siemens Healthineers Company
Not applicable
20
Missouri, Ohio
2026-07-31
Recruiting
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
NCT07708727HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2/3
700
Florida, Georgia, Missouri, Texas
2026-07-29
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795Colorectal Cancer
DrugsVS-7375·Panitumumab·MFOLFOX6·Cetuximab
Verastem, Inc.
Phase 2
150
California, Florida, Indiana, Michigan, Missouri, New Jersey, New York, Tennessee
2026-07-28
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596Relapsed or Refractory Multiple Myeloma
DrugsAldesleukin·Daratumumab
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07704892Metabolic Dysfunction-associated Steatohepatitis
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
380
Arkansas, California, Florida, Missouri, New York, North Carolina, Ohio, Texas
2026-07-22
Recruiting
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07701993Metabolic Dysfunction-associated Steatohepatitis
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,740
Arkansas, California, Florida, Missouri, Texas
2026-07-22
Recruiting
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
NCT07594106Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
DrugsREGN4336·Cemiplimab
Regeneron Pharmaceuticals
Phase 1/2
265
Arizona, California, Florida, Illinois, Missouri, Texas
2026-07-20
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma
NCT07532265Severe Asthma
Kinaset Therapeutics Inc
Phase 2
512
California, Florida, Illinois, Missouri, North Carolina, Pennsylvania, South Carolina, Texas
2026-07-16
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsRilvegostomig·Enfortumab Vedotin·Dato-DXd·Opdivo
AstraZeneca
Phase 3
915
Arkansas, California, Illinois, Massachusetts, Missouri, Nebraska, New York, Ohio
2026-07-16
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
NCT07682961HIV Infections
DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
NCT07516951Idiopathic Pulmonary Fibrosis
Chiesi Farmaceutici S.p.A.
Phase 2
240
Missouri, Texas
2026-07-08
Active, closed
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
NCT07717840RSV Respiratory Syncytial Virus
AstraZeneca
Phase 1/2
164
California, Illinois, Kansas, Missouri, Nebraska
2026-07-08
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
DrugElecoglipron
AstraZeneca
Phase 3
900
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2026-07-06
Not yet open
Study of the Shockwave Medical SkyRunner Carotid Intravascular Lithotripsy (IVL) System for the Treatment of Calcified Carotid Arteries Prior to Trans-Femoral Stenting (SKYWARD Trans-Femoral IDE [Investigational Device Exemption] Study)
NCT07512128Carotid Artery Calcification, Carotid Artery Diseases
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Recruiting
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
NCT07695701Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
Eidos Therapeutics, a BridgeBio company
Phase 4
150
Missouri
2026-07
Not yet open
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
NCT07218185Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Cerus Corporation
Observational
320
Colorado, Florida, Maryland, Missouri
2026-07
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
NCT07581002Acute Myeloid Leukemia
DrugsPivekimab Sunirine·Azacitidine·Venetoclax
AbbVie
Phase 2/3
660
California, Florida, Georgia, Missouri, New York, Texas
2026-06-30
Active, closed
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122Obesity, Overweight
DrugBI 3034701
Boehringer Ingelheim
Phase 2
344
Alabama, California, Florida, Georgia, Kentucky, Michigan, Missouri, North Carolina
2026-06-30
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
NCT07589634Multiple Myeloma
DrugsRamantamig·Tocilizumab
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri
2026-06-30
Recruiting
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT07671911Idiopathic Pulmonary Fibrosis
DrugNalbuphine
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Louisiana, Missouri, North Carolina, Pennsylvania, South Carolina
2026-06-29
Recruiting
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
Moonlight Bio, Inc
Phase 1
110
Missouri, New Jersey, New York, Tennessee, Texas
2026-06-23
Recruiting
Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis
NCT07122518Pulmonary Artery Stenosis
Cordis US Corp.
Observational
35
California, Georgia, Michigan, Missouri, Nebraska, Ohio, Pennsylvania, Texas
2026-06-23
By invitation
An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD
NCT07670702Post Traumatic Stress Disorder
DrugMethylone
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
DrugsVS-7375·Cetuximab
Verastem, Inc.
Phase 2
180
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey
2026-06-16
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
DrugsGS-3242·B/F/TAF·Lenacapavir
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Active, closed
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727Obesity and Cardiovascular Risk
DrugBGE-102
BioAge Labs, Inc.
Phase 2
160
Arizona, Arkansas, Florida, Kentucky, Maryland, Missouri, Nevada, New York
2026-06-11
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey, North Carolina
2026-06-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugsCliramitug·Eplontersen
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
NCT07570316Graves' Disease, Graves Disease
DrugEfgartigimod PH20
argenx
Phase 3
230
California, Florida, Kansas, Michigan, Missouri, New York, Texas
2026-06-10
Active, closed
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021Obesity
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
233
Alabama, California, Florida, Illinois, Indiana, Kentucky, Maryland, Missouri
2026-06-09
Recruiting
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
NCT07448038Atherosclerosis
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820Atopic Dermatitis
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902Persistent Corneal Epithelial Defect
DrugCenegermin
Dompé Farmaceutici S.p.A
Phase 3
150
California, Florida, Massachusetts, Michigan, Missouri, New York, North Carolina, South Dakota
2026-06-02
Recruiting
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
NCT07661329Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
YS Life Science Co., Ltd.
Phase 3
600
California, Florida, Georgia, Kentucky, Missouri, Texas
2026-06-02
Recruiting
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
NCT07625293Crohn Disease (CD)
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Missouri
2026-06-01
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
DrugTARA-002
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
By invitation
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
NCT07832552Postoperative Ocular Inflammation, Postoperative Ocular Pain
Harrow Inc
Phase 3
250
Missouri
2026-05-25
Recruiting
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
NCT07479797Relapsed or Refractory Large B-cell Lymphoma
DrugsKITE-753·Axicabtagene Ciloleucel·Fludarabine·Cyclophosphamide
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri
2026-05-22
Recruiting
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616Meningioma
DrugZanzalintinib
Exelixis
Phase 2
100
Alabama, Arizona, California, Florida, Louisiana, Massachusetts, Missouri, New York
2026-05-21
Recruiting
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470Alzheimer Disease
Alpha Cognition, Inc
Phase 4
150
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2026-05-20
Recruiting
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
NCT07527858Advanced Microsatellite Stable Colorectal Cancer
DrugsDenikitug·Trifluridine/Tipiracil·Nivolumab·Bevacizumab
Gilead Sciences
Phase 2
170
Connecticut, Massachusetts, Missouri, South Dakota, Virginia
2026-05-19
Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650Type 2 Diabetes Mellitus, T2DM
DrugHM15275
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
California, Florida, Georgia, Indiana, Maryland, Missouri, New York, North Carolina
2026-05-14
Recruiting
A Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers
NCT07598136Smoking, Tobacco
RAI Services Company
Not applicable
1,280
Florida, Georgia, Missouri, North Carolina, Pennsylvania, Texas
2026-05-14
Recruiting
Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
NCT06930755Ovarian Cancer
DrugsNMS-03305293·Topotecan
Nerviano Medical Sciences
Phase 1
24
Illinois, Missouri, Pennsylvania, Tennessee, Texas
2026-05-13
Recruiting
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886Dry Eye Disease (DED)
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease
NCT07354724Late-onset Pompe Disease
Denali Therapeutics Inc.
Phase 1
32
California, Missouri, North Carolina, Virginia
2026-05-12
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
DrugSarilumab
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
Stunting and Targeting Reduction of Impaired Growth in Kids Effectively
NCT07524907Malnutrition (Calorie)
Abbott Nutrition
Observational
158
Missouri
2026-05-11
Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
NCT07441694Myeloproliferative Neoplasms
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
NCT07296744Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Supira Medical
Not applicable
358
California, Georgia, Illinois, Michigan, Minnesota, Missouri, New Jersey, New York
2026-05-11
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
NCT07566156Urothelial Cancer, Urinary Bladder Neoplasms
DrugsMitomycin C·Enfortumab Vedotin·Fluorouracil·Keytruda
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Recruiting
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
NCT07592689Major Depressive Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
NCT07543120Hypertension (HTN)
DrugQCZ484
Novartis Pharmaceuticals
Phase 2
323
California, Florida, Georgia, Illinois, Kansas, Maryland, Michigan, Missouri
2026-05-07
Recruiting
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
NCT07610837Liver Fibrosis, Hepatic Cirrhosis
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Bevacizumab
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York, Tennessee
2026-05-06
Recruiting
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
NCT07427394Advanced Breast Cancer
DrugsAtirmociclib·Camizestrant
AstraZeneca
Phase 2
24
Missouri, Rhode Island, Tennessee
2026-05-06
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Illinois, Missouri, Montana, Nebraska, Nevada
2026-05-04
Recruiting
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
NCT07490301Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
DrugsTelisotuzumab Adizutecan·Fluorouracil·Irinotecan·Oxaliplatin
AbbVie
Phase 2/3
900
Connecticut, Illinois, Michigan, Missouri, Ohio, Pennsylvania, Texas, Virginia
2026-04-30
Recruiting
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
NCT07554521Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine
BeOne Medicines
Phase 2
30
California, Florida, Missouri, Ohio
2026-04-30
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
NCT07232030Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III
CVRx, Inc.
Not applicable
2,500
Alabama, Florida, Missouri, Nebraska, Ohio, South Dakota, Tennessee, Texas
2026-04-24
Recruiting
PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
NCT07429240Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Precision BioSciences, Inc.
Phase 1/2
18
Arkansas, Missouri
2026-04-24
By invitation
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
NCT07393373Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
52-week Open Label Safety-Tolerability Study
NCT07369154Schizophrenia
DrugLB-102
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis
NCT07303777Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
DrugsABP-745 A·ABP-745 B
Atom Therapeutics Co., Ltd
Phase 2
200
California, Missouri
2026-04-23
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NCT07611214Lupus Nephritis
DrugsLupkynis·Anifrolumab
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
Donidalorsen Treatment in Children With Hereditary Angioedema
NCT07298447Hereditary Angioedema (HAE)
DrugDonidalorsen
Ionis Pharmaceuticals, Inc.
Phase 3
20
California, Florida, Louisiana, Missouri, Ohio, Pennsylvania, Wisconsin
2026-04-21
By invitation
Investigation of a Patient Support Intervention for Statin Medication Adherence
NCT06972979Medication Adherence
Ascension Health
Not applicable
2,200
Missouri
2026-04-20
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07509307Obesity, Overweight, Osteoarthritis, Knee
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
Recruiting
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
NCT07507422Chronic Pain, Intractable Pain
Medtronic
Observational
970
Arizona, California, Missouri, Texas
2026-04-17
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes
NCT07415954Diabetes Mellitus, Type 2
DrugsNNC0662-0419·Semaglutide
Novo Nordisk A/S
Phase 2
270
California, Florida, Idaho, Illinois, Massachusetts, Missouri, North Carolina, Ohio
2026-04-17
By invitation
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
NCT07444489Antibody-mediated Rejection, Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
NCT07264959Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311Multiple Myeloma
DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT07545811Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer
Janux Therapeutics
Phase 1
43
California, Missouri, South Carolina, Tennessee, Texas
2026-04-15
Recruiting
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
NCT07525375Asthma
AstraZeneca
Phase 2
69
California, Florida, Kentucky, Louisiana, Massachusetts, Missouri, Ohio, Oklahoma
2026-04-14
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
84
Massachusetts, Missouri, New Jersey, Texas
2026-04-13
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495Carcinoma, Renal Cell
DrugsZanzalintinib·Belzutifan
Merck Sharp & Dohme LLC
Phase 3
758
Georgia, Missouri, New York, Tennessee
2026-04-09
Recruiting
Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)
NCT07298473Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF)
Medtronic Cardiac Ablation Solutions
Not applicable
400
Alabama, California, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2026-04-08
Active, closed
A Pivotal Study to Evaluate the Clinical Benefit, Performance and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults
NCT07287124Hearing Loss, Bilateral Sensorineural
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Florida, Maryland, Michigan, Missouri, Nevada
2026-04-02
Not yet open
H-Wave® Device Stimulation for Post-operative Rotator Cuff Repair Surgery
NCT07501949Rotator Cuff Tear Surgical Repair
Electronic Waveform Lab
Not applicable
80
Kansas, Missouri
2026-04-01
Recruiting
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
NCT07363577Schizophrenia
DrugLB-102
LB Pharmaceuticals Inc.
Phase 3
456
Arkansas, California, Florida, Georgia, Illinois, Missouri, Ohio
2026-03-25
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, Missouri
2026-03-25
Recruiting
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
NCT07463183Colitis Ulcerative, Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019Secondary Progressive Multiple Sclerosis
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
990
Arizona, California, Florida, Indiana, Kansas, Massachusetts, Michigan, Missouri
2026-03-23
Recruiting
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463Multiple Sclerosis (MS) Primary Progressive
DrugOrelabrutinib
Zenas BioPharma (USA), LLC
Phase 3
705
Arizona, California, Florida, Kansas, Missouri, New Jersey, North Carolina, Ohio
2026-03-23
Recruiting
Post Approval Effectiveness and Durability Evaluation of the Altaviva™ Tibial Device
NCT07456865Urge Urinary Incontinence
MedtronicNeuro
Not applicable
256
Alabama, Idaho, Missouri, North Carolina, Ohio, Pennsylvania, South Carolina, South Dakota
2026-03-17
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Michigan, Minnesota, Missouri, New York
2026-03-16
Recruiting
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
NCT07467993Schizophrenia
Novartis Pharmaceuticals
Phase 2
142
Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Arizona, California, Florida, Georgia, Illinois, Iowa, Minnesota, Missouri
2026-03-13
By invitation
Long-Term Open-Label Extension Study of Oral Levosimendan
NCT07436689Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
800
Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina, South Carolina, Wisconsin
2026-03-13
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
Recruiting
A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07450859Pancreatic Ductal Adenocarcinoma (PDAC)
DrugNuzefatide pevedotin
BicycleTx Limited
Phase 2
39
Arizona, Florida, Minnesota, Missouri, New York, Pennsylvania
2026-03-05
Active, closed
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252Overweight or Obesity and Elevated Liver Fat
DrugMaridebart cafraglutide
Amgen
Phase 2
180
Arizona, California, Florida, Louisiana, Maryland, Missouri, Nevada, Texas
2026-03-05
Recruiting
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
NCT07226895Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
NCT07374848Solid Tumors, Sarcomas
Zai Lab (Shanghai) Co., Ltd.
Phase 1
180
California, Connecticut, Florida, Missouri, New York, Virginia
2026-03-02
Recruiting
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive
DrugBendamustine
Tr1X, Inc.
Phase 1/2
39
California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington
2026-03-01
Active, closed
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
DrugBerobenatide
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
NCT07339423Obesity
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
1,150
Florida, Georgia, Illinois, Indiana, Missouri, New York, North Carolina, Pennsylvania
2026-02-24
Recruiting
A Study to Learn About mRNA Vaccines Against Influenza in Adults
NCT07431853Healthy Adults
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
Study of DISC-0974-201 in Participants With IBD and Anemia
NCT07368972Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
DrugDISC-0974
Disc Medicine, Inc
Phase 2
21
Alabama, Arizona, California, Florida, Missouri, Ohio, Rhode Island, Texas
2026-02-20
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis
NCT07568730Neurotrophic Keratitis
TearSolutions, Inc.
Phase 2
54
Florida, Indiana, Massachusetts, Minnesota, Missouri, New York
2026-02-19
Recruiting
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
NCT07368998Breast Cancer
DrugsInavolisib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
California, Florida, Missouri, New Jersey
2026-02-18
Recruiting
Ambulatory Long Length URodynamics Evaluation
NCT07425015Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics
Bright Uro
Not applicable
101
Louisiana, Maryland, Missouri, Ohio, South Carolina, South Dakota, Texas, Washington
2026-02-17
Recruiting
Agilis RF TSP Early Feasibility Study
NCT07361445Cardiac Arrythmias, Left Atrial Appendage Closure
Abbott Medical Devices
Not applicable
60
Arkansas, California, Missouri
2026-02-16
Recruiting
A Study of Patients With Fabry Disease (US Specific)
NCT06906367Fabry Disease
DrugMigalastat HCl
Amicus Therapeutics
Observational
450
Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia
2026-02-13
Recruiting
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
NCT07215273Invasive Mould Infection
DrugVoriconazole
Elion Therapeutics, Inc.
Phase 2
60
Alabama, California, Georgia, Maryland, Massachusetts, Michigan, Missouri, Texas
2026-02-13
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dovato·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
NCT07197944Short Bowel Syndrome
DrugGlepaglutide
Zealand Pharma
Phase 3
90
Illinois, Missouri, Nebraska, New York, Pennsylvania, Tennessee
2026-02-11
Recruiting
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
NCT07392372HIV -1 Infection
BioNTech SE
Phase 1
67
Illinois, Maryland, Missouri, New York
2026-02-09
Recruiting
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
NCT07250750Myasthenia Gravis
ImmunAbs Inc.
Phase 1/2
96
Florida, Missouri, Texas
2026-02-05
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
NCT06696755Bipolar I Disorder, Bipolar II Disorder
DrugIcalcaprant
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Recruiting
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH
Phase 2/3
300
California, Indiana, Mississippi, Missouri, New York, Ohio, Oregon, Vermont
2026-02-02
Recruiting
Remibrutinib in Real-world Clinical Practice - a US Sub-study
NCT07358780Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
505
Missouri
2026-02-02
Recruiting
Remibrutinib in Real-world Clinical Practice
NCT07358364Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Observational
3,280
Missouri
2026-02-02
Active, closed
Evaluation of Lumitrace for Visualizing Ureters During Abdominopelvic Surgeries
NCT07080008Ureter Injury
MediBeacon
Phase 1
10
Missouri
2026-01-30
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
DrugsGocatamig·Ifinatamab Deruxtecan·Etoposide·Atezolizumab
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
LTZ Therapeutics, Inc.
Phase 1
42
California, Missouri, New York, Tennessee, Washington
2026-01-29
Recruiting
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
NCT07154823Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Tempus AI
Observational
550
Iowa, Maryland, Missouri, Nevada, North Carolina, Ohio, Pennsylvania, South Dakota
2026-01-27
Recruiting
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305Bipolar I Disorder
DrugLB-102
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288Idiopathic Pulmonary Fibrosis
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Indiana, Louisiana, Michigan, Missouri
2026-01-16
Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480Multiple Myeloma, Secondary Immunodeficiency
Takeda
Phase 3
183
Alabama, California, Kansas, Maryland, Michigan, Missouri, New York
2026-01-14
Recruiting
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV), Juvenile Myasthenia Gravis, Juvenile Dermatomyositis
DrugDescartes-08
Cartesian Therapeutics
Phase 1/2
50
District of Columbia, Missouri, Ohio
2026-01-14
Recruiting
A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
NCT07300267Pneumococcal Infection
DrugPrevnar 20
Merck Sharp & Dohme LLC
Phase 1
210
California, Florida, Kansas, Kentucky, Maryland, Missouri, New York, South Carolina
2026-01-13
Recruiting
DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
NCT07358078Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Observational
2,000
Arizona, California, Florida, Kansas, Massachusetts, Missouri, New Jersey, North Carolina
2026-01-09
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington
2026-01-09
Recruiting
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07290062Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC
Phase 1
23
California, Maryland, Massachusetts, Missouri, Ohio, Pennsylvania
2026-01-09
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
NCT07219043Microvascular Inflammation
DrugFelzartamab
Biogen
Phase 2
81
California, Colorado, Kansas, Michigan, Minnesota, Missouri, Nebraska, New Jersey
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Recruiting
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
NCT07815678Obesity
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Phase 1/2
164
California, Georgia, Minnesota, Missouri, Texas
2025-12-29
Recruiting
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
NCT07265947Low Grade Upper Tract Urothelial Carcinoma
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
230
California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan, Missouri
2025-12-22
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Active, closed
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850Obesity and Overweight
DrugBerobenatide
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
NCT07266831Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
NCT07091019Chronic Myelogenous Leukemia - Chronic Phase
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639Hemoglobinopathy, Sickle Cell Disease
Beam Therapeutics Inc.
Observational
50
Alabama, Arizona, Florida, Georgia, Massachusetts, Michigan, Minnesota, Missouri
2025-12-15
Recruiting
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188Non-alcoholic Fatty Liver Disease
DrugEfimosfermin alfa
GlaxoSmithKline
Phase 3
1,250
California, Florida, Kansas, Louisiana, Missouri, New Jersey, New York, North Carolina
2025-12-12
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
DrugAGA2115
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474Squamous Non-small Cell Lung Cancer
DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 2
180
Florida, Michigan, Missouri, New Jersey, New York, Ohio, Oregon, Tennessee
2025-12-12
Recruiting
NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
NCT06604884Intracranial Aneurysm
Medtronic Neurovascular Clinical Affairs
Observational
118
Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri, South Carolina
2025-12-12
Recruiting
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
NCT07214571Respiratory Syncytial Virus Infections
Shionogi
Phase 2
192
California, Florida, Georgia, Massachusetts, Missouri, New York, North Carolina, Ohio
2025-12-11
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
DrugBG-75202
BeOne Medicines
Phase 1
86
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
Ultrasonic Neuromodulation of Cingulate Cortex for Fibromyalgia
NCT07226648Fibromyalgia
SPIRE Therapeutics Inc.
Not applicable
180
Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah, West Virginia
2025-12-11
Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
NCT07224373Multiple Sclerosis
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin
2025-12-09
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
By invitation
Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic
NCT07417774Glioblastoma (GBM)
NuvOx LLC
Observational
40
Arizona, Connecticut, Missouri, North Carolina
2025-12-08
Recruiting
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
RayzeBio, Inc.
Phase 1
104
Arizona, Florida, Iowa, Kentucky, Minnesota, Missouri, Ohio, Oregon
2025-12-03
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Alabama, California, Florida, Missouri, Texas
2025-12-02
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
DrugAbrocitinib
Pfizer
Phase 3
500
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-12-02
Recruiting
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
NCT07284186Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Plexium, Inc.
Phase 1
155
Arizona, California, Massachusetts, Missouri, New York, North Carolina, Ohio, Texas
2025-12-01
Recruiting
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
NCT07395232Atopic Keratoconjunctivitis
DrugDFL24498
Dompé Farmaceutici S.p.A
Phase 3
153
Florida, Georgia, Missouri, New York, North Carolina, Tennessee, Texas
2025-12-01
Active, closed
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
NCT07400588Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
DrugAleniglipron
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
58
Alabama, California, Missouri, Ohio, South Carolina, Tennessee, Texas
2025-12-01
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
DrugsPF-08634404·Yervoy·Ipilimumab
Pfizer
Phase 1/2
138
California, Florida, Illinois, Minnesota, Missouri, Nevada, North Carolina, Ohio
2025-12-01
Recruiting
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT06930625Acromegaly
Debiopharm International SA
Phase 3
119
California, Illinois, Massachusetts, Missouri, Nevada, New York, Ohio, Oregon
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
DrugsABBV-706·Lurbinectedin·Etoposide·Atezolizumab
AbbVie
Phase 2
180
Connecticut, Florida, Indiana, Kentucky, Massachusetts, Michigan, Missouri, Ohio
2025-11-25
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Active, closed
A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections
NCT07232004Healthy Volunteer
AbbVie
Phase 1
121
Alabama, Arkansas, California, Florida, Illinois, Massachusetts, Minnesota, Missouri
2025-11-24
Active, closed
Taldefgrobep Alfa in Adults With Overweight and Obesity
NCT07281495Obesity, Overweight
DrugTaldefgrobep alfa
Biohaven Therapeutics Ltd.
Phase 2
150
California, Florida, Illinois, Indiana, Louisiana, Missouri, North Carolina, North Dakota
2025-11-24
Recruiting
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
DrugFinerenone
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
223
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Recruiting
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
NCT07144345Actinic Keratosis
Sun Pharmaceutical Industries, Inc.
Phase 3
160
California, Florida, Illinois, Indiana, Minnesota, Missouri, Oregon, South Carolina
2025-11-19
Recruiting
Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA
NCT07026877Abdominal Aortic Aneurysms (AAA)
Bolton Medical
Not applicable
20
Colorado, Florida, Massachusetts, Missouri, New York, Texas, Washington
2025-11-18
Active, closed
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719Obesity, Overweight
DrugRetatrutide
Eli Lilly and Company
Phase 3
250
California, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri, New Jersey
2025-11-17
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Active, closed
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT07036523Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim
Phase 2
81
Alabama, Florida, Iowa, Kansas, Minnesota, Missouri, New York, North Carolina
2025-11-13
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
NCT07170917Hidradenitis Suppurativa
DrugBrivekimig
Sanofi
Phase 2
208
Arizona, California, Florida, Georgia, Iowa, Louisiana, Missouri, Nevada
2025-11-06
Active, closed
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642Obesity, Overweight
DrugCagrilintide
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Recruiting
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT07219511Heart, Heart Failure With Preserved Ejection Fraction (HFPEF)
Vasa Therapeutics
Phase 1
42
Arkansas, California, Florida, Illinois, Louisiana, Missouri, New Jersey, New York
2025-11-04
Recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
NCT07223840Smoking
DrugBrenipatide
Eli Lilly and Company
Phase 2
222
Arkansas, Florida, Georgia, Michigan, Missouri, Nevada, New York, South Carolina
2025-11-03
Recruiting
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
NCT07098858Heart Failure
EBR Systems, Inc.
Observational
320
Arizona, Arkansas, Florida, Michigan, Missouri, New York, Ohio, Pennsylvania
2025-11-03
Recruiting
CCM OPEN HF Registry
NCT07112924Heart Failure
Impulse Dynamics
Observational
5,500
Arizona, Florida, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New Hampshire
2025-11-01
Recruiting
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
NCT07123155Pompe Disease
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Florida, Louisiana, Maryland, Michigan, Missouri, New Jersey, New York, Pennsylvania
2025-10-27
Recruiting
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer
Tempus AI
Observational
900
Alabama, California, Florida, Illinois, Indiana, Michigan, Missouri, Nevada
2025-10-27
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
California, Florida, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2025-10-22
Recruiting
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
NCT07266805Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
48
California, Missouri, Pennsylvania
2025-10-16
Active, closed
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
NCT07008378Multiple Sclerosis
DrugsFludarabine·Cyclophosphamide
Genentech, Inc.
Phase 1
60
California, Missouri, New Jersey, New York
2025-10-15
Active, closed
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NCT07161635Aphakia, Presbyopia
Alcon Research
Not applicable
110
California, Missouri, South Carolina, Texas, Utah
2025-10-14
Active, closed
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312Diabetes Mellitus, Type 2
DrugsLY3938577·Degludec
Eli Lilly and Company
Phase 2
100
Arizona, California, Florida, Iowa, Missouri, North Carolina, Oklahoma, South Carolina
2025-10-13
Active, closed
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
NCT07157254Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 2
60
California, Illinois, Maryland, Missouri, North Carolina, Ohio, Texas
2025-10-13
Recruiting
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2
140
Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington
2025-10-09
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
A Study of V118E in Healthy Participants (V118E-003)
NCT07168915Healthy
DrugPrevnar 20
Merck Sharp & Dohme LLC
Phase 1
126
Florida, Missouri, Texas
2025-10-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
DrugKarXT
Bristol-Myers Squibb
Phase 3
424
Arkansas, California, Florida, Georgia, Illinois, Missouri, New York, Texas
2025-10-08
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908NSCLC Stage IV
DrugsTislelizumab·Docetaxel
ImmunityBio, Inc.
Phase 3
507
Arkansas, California, Florida, Georgia, Missouri, North Carolina, Ohio, South Carolina
2025-10-01
By invitation
Enhanced Sternal Closure With Montage or Montage-CT to Evaluate Post-Operative Opioid Use Following Median Sternotomy
NCT07215546Retrospective Review, Cerclage, Pain Management
Abyrx, Inc.
Observational
150
Florida, Missouri
2025-10
Recruiting
Clinical Course Of Disease In Participants With FA-CM
NCT06865482Friedreich Ataxia, Cardiomyopathy
Lexeo Therapeutics
Observational
65
California, Florida, Indiana, Massachusetts, Minnesota, Missouri, Ohio, Oregon
2025-09-30
Recruiting
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
NCT06813820Left Ventricle Remodeling, Left Ventricle Dilated, CHF
BioVentrix
Not applicable
135
Arizona, Florida, Illinois, Missouri, Oklahoma, Pennsylvania
2025-09-29
Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
NCT07204340KRAS Mutant Solid Tumors
DrugsCetuximab·Pembrolizumab
Treeline Biosciences, Inc.
Phase 1
270
Alabama, Massachusetts, Michigan, Missouri, New York, Tennessee
2025-09-29
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Florida, Illinois, Maryland, Missouri, Montana, Nebraska
2025-09-26
Recruiting
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874Colon Cancer, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Cancer
Pheon Therapeutics
Phase 1
165
California, District of Columbia, Massachusetts, Missouri, North Carolina, Oregon, Tennessee, Texas
2025-09-23
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Active, closed
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578Social Anxiety Disorder (SAD)
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Recruiting
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Illinois, Missouri
2025-09-18
Not yet open
LTFU for All Cell and Gene Therapy Studies
NCT06194461Hepatocellular Carcinoma, Prostate Cancer
DrugsAZD0754·AZD5851
AstraZeneca
Observational
64
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, Missouri
2025-09-17
Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758Extensive Stage Small Cell Lung Cancer
DrugsEtakafusp alfa·Tarlatamab
Amgen
Phase 1
380
Arizona, California, Florida, Georgia, Kentucky, Massachusetts, Missouri, New York
2025-09-16
Recruiting
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161Hypertension, Uncontrolled Hypertension
DrugIloperidone
Vanda Pharmaceuticals
Phase 2
240
Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky, Missouri
2025-09-15
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
DrugsNavlimetostat·Iza-bren
Bristol-Myers Squibb
Phase 2
182
Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington
2025-09-09
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
ColoSense Post-Approval Study
NCT07069556Colorectal Cancer (Diagnosis)
Geneoscopy, Inc.
Observational
12,500
Missouri
2025-09-05
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
NCT06726161Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.
Phase 1/2
590
Alabama, Arizona, California, Florida, Kentucky, Maryland, Minnesota, Missouri
2025-09-05
Active, closed
A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)
NCT07128615Influenza A
AstraZeneca
Phase 1/2
405
California, Florida, Georgia, Illinois, Kansas, Missouri, Nebraska, Nevada
2025-09-04
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707Obesity
MBX Biosciences
Phase 1
124
Florida, Kentucky, Missouri, Tennessee
2025-09-03
By invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine
BeOne Medicines
Phase 3
351
Arizona, California, Colorado, Florida, Illinois, Kansas, Maine, Missouri
2025-08-27
Recruiting
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
NCT07191483Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.
Phase 2
150
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey
2025-08-27
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
NCT06966024Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC
Phase 1
60
Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Tennessee, Texas
2025-08-27
Recruiting
SLV-324 Treatment of Metastatic Solid Tumors
NCT07108114Metastatic Solid Tumors
Solve Therapeutics
Phase 1
70
California, Missouri, Ohio, Pennsylvania, Texas, Washington
2025-08-25
Recruiting
IDOV-Immune for Advanced Solid Tumors
NCT06910657Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
DrugIDOV-Immune
ViroMissile, Inc.
Phase 1
78
Missouri, Texas
2025-08-25
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
DrugAZD0120
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
Arizona, California, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2025-08-18
Recruiting
PSMA PET Combined With MRI for the Detection of PCa
NCT07052214PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
DrugIlluccix
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
338
California, Florida, Illinois, Indiana, Louisiana, Missouri, New York, Pennsylvania
2025-08-18
Recruiting
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Active, closed
Aleniglipron Phase 2 Body Composition Study
NCT07169942Obesity, Overweight, or Chronic Weight Management
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 2
71
Arizona, Illinois, Minnesota, Missouri, New York, North Carolina, Oklahoma, South Carolina
2025-08-15
Recruiting
The DistaSense VITALS Study
NCT07217327Detection of Heart Rate and Respiratory Rate
Life Detection Technologies
Observational
20
Missouri, Ohio
2025-08-13
Active, closed
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
NCT06985147Polycythemia Vera (PV)
DrugDISC-3405
Disc Medicine, Inc
Phase 2
60
Arizona, California, Florida, Minnesota, Missouri, North Carolina, Ohio, Oregon
2025-08-12
Recruiting
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
400
Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri, Nevada
2025-08-08
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
DrugVHB937
Novartis Pharmaceuticals
Phase 2
407
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06896916Multiple Myeloma
DrugsEtentamig·Iberdomide
AbbVie
Phase 1
135
California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington
2025-08-07
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
DrugIVIG
CSL Behring
Phase 2
70
California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan, Missouri
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
California, Florida, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania
2025-08-06
Active, closed
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
NCT07092865Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 2
168
Kentucky, Missouri, Nebraska, New York, Pennsylvania, Texas
2025-08-06
Recruiting
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
DrugsPalbociclib·Fulvestrant
Bristol-Myers Squibb
Phase 1
234
Alabama, California, Colorado, Massachusetts, Missouri, New Hampshire, New York, Texas
2025-08-01
Recruiting
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
NCT07073547Multiple Myeloma
DrugAZD0120
AstraZeneca
Phase 1
40
Arizona, California, Colorado, Florida, Georgia, Iowa, Minnesota, Missouri
2025-07-31
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
DrugsPanitumumab·Pembrolizumab
Amgen
Phase 1
434
California, Georgia, Massachusetts, Missouri, North Carolina, Pennsylvania, Tennessee, Texas
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Arizona, California, District of Columbia, Illinois, Maryland, Minnesota, Missouri, Texas
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
A Study of LY4175408 in Participants With Advanced Cancer
NCT07046923Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
DrugsCisplatin·Carboplatin·Pembrolizumab
Eli Lilly and Company
Phase 1
240
California, Florida, Illinois, Indiana, Massachusetts, Missouri, New Jersey, New York
2025-07-28
Active, closed
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
NCT07046494Bipolar 1 Disorder
DrugRAP-219
Rapport Therapeutics Inc.
Phase 2
253
Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri, New York
2025-07-25
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244Acute Ischemic Stroke, Cerebral Stroke
DrugSovateltide
Pharmazz, Inc.
Phase 3
514
Arizona, California, Florida, Georgia, Missouri, New Jersey, North Carolina, Ohio
2025-07-24
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
DrugAbrocitinib
Pfizer
Phase 3
150
Alabama, Arkansas, California, Florida, Idaho, Indiana, Missouri, South Carolina
2025-07-24
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
California, Florida, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska
2025-07-24
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634Breast Cancer
DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole
Celcuity Inc
Phase 3
1,180
California, Florida, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Missouri
2025-07-24
Active, closed
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677Streptococcus Pneumoniae
DrugPrevnar 20
Pfizer
Phase 1
380
California, Florida, Kansas, Missouri, Nebraska, New York, North Carolina, Ohio
2025-07-22
Recruiting
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
NCT07356453Advanced Solid Tumors
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Arizona, Florida, Illinois, Kentucky, Maryland, Missouri, New Jersey
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
California, District of Columbia, Kansas, Maryland, Missouri, New York, North Carolina, Ohio
2025-07-18
Recruiting
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
NCT06779630Coronary Artery Disease
Teleflex
Not applicable
150
California, Kansas, Massachusetts, Michigan, Missouri, New York, Texas, West Virginia
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
NCT06994676High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Crossbow Therapeutics, Inc.
Phase 1
72
California, Florida, Illinois, Massachusetts, Missouri, New York, Pennsylvania, Tennessee
2025-07-16
Recruiting
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494Early Alzheimer's Disease
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070Heart Transplant, Heart Failure, Transplant; Failure, Heart
XVIVO Perfusion
Not applicable
60
California, Georgia, Illinois, Missouri, Nebraska, New York, North Carolina, Tennessee
2025-07-10
Active, closed
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384HIV Infections
DrugsVH3810109·Fostemsavir
ViiV Healthcare
Phase 1
107
California, Florida, Illinois, Missouri, New York, Ohio, Pennsylvania, Texas
2025-07-10
Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
NCT06915025Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
DrugsIMNN-001·Niraparib·Olaparib·Paclitaxel
Imunon
Phase 3
500
Florida, Louisiana, Minnesota, Missouri, Oregon, South Dakota, Tennessee, Washington
2025-07-09
Active, closed
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
DrugBrivekimig
Sanofi
Phase 2
99
California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri, New York
2025-07-07
Recruiting
A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis
NCT06999733Neurotrophic Keratitis
Krystal Biotech, Inc.
Phase 1/2
60
California, Indiana, Minnesota, Missouri, New Jersey, North Dakota, Pennsylvania
2025-07-07
Not yet open
Assessment of Flow in Cerebrospinal Fluid Shunts With a Second Generation Wireless Thermal Anisotropy Measurement Device
NCT06409286Hydrocephalus
Rhaeos, Inc.
Observational
17
Missouri
2025-07
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
NCT06998524Von Willebrand Disease, Type 3
DrugEmicizumab
Hoffmann-La Roche
Phase 3
75
California, Florida, Kentucky, Minnesota, Missouri, Virginia
2025-06-27
Active, closed
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
NCT07119125Healthy Volunteers, Elevated CRP
Monte Rosa Therapeutics, Inc
Phase 1
100
Florida, Kansas, Missouri, Texas
2025-06-27
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Lymphoma, Lymphoma, Non Hodgkin
DrugZeprumetostat
Treeline Biosciences, Inc.
Phase 1
180
California, Michigan, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-06-23
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095Pulmonary Disease, Chronic Obstructive
DrugDepemokimab
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
210
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Missouri
2025-06-19
Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
DrugGlyphAllo
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Recruiting
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
NCT06283979Pressure Ulcer, Stage IV, Osteomyelitis
Biocomposites Ltd
Phase 2
60
Arizona, Illinois, Michigan, Mississippi, Missouri, Nebraska, New Jersey, New York
2025-06-15
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
DrugKarXT
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Florida, Georgia, Illinois, Maryland, Mississippi, Missouri
2025-06-13
Active, closed
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
NCT06914609Angelman Syndrome
DrugObudanersen
Ionis Pharmaceuticals, Inc.
Phase 3
156
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts, Missouri
2025-06-10
Recruiting
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
NCT06782490Multiple Sclerosis Spasticity
DrugIrafamdastat
Celgene
Phase 2
200
Alabama, Arizona, Colorado, Florida, Kansas, Massachusetts, Michigan, Missouri
2025-06-05
Active, closed
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667Obesity
DrugCagriSema
Novo Nordisk A/S
Phase 3
609
California, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, Missouri
2025-06-03
Recruiting
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564Advanced Solid Tumors
DrugJAB-23E73
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
294
Minnesota, Missouri, Ohio, Utah
2025-05-29
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
DrugPatritumab deruxtecan
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
NCT07680244Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
Carl Zeiss Meditec-Dublin CoCe
Not applicable
400
Arizona, California, Florida, Maine, Missouri
2025-05-23
Recruiting
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
NCT06682793Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
A2 Biotherapeutics Inc.
Phase 1/2
240
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington
2025-05-22
Recruiting
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
NCT06697301Advanced Melanoma
DrugsEIK1001·Keytruda·Pembrolizumab
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Florida, Maryland, Missouri, Ohio
2025-05-22
Recruiting
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808Perianal Fistula Due to Crohn's Disease
DrugDB-3Q
Direct Biologics, LLC
Phase 2
36
Colorado, Missouri, New York, Pennsylvania, Tennessee
2025-05-19
Active, closed
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT06970847Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant
Drug64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Phase 3
220
California, Florida, Illinois, Indiana, Louisiana, Minnesota, Missouri, Nebraska
2025-05-16
Active, closed
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
NCT06898957Small Cell Lung Cancer
DrugsTam-Peli·Tarlatamab·Durvalumab
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Recruiting
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968Schizophrenia
DrugIloperidone
Vanda Pharmaceuticals
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, Mississippi, Missouri, Nevada
2025-05-14
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Solve Therapeutics
Phase 1
250
California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington
2025-05-14
Recruiting
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Phase 2
36
California, Florida, Georgia, Massachusetts, Minnesota, Missouri, Pennsylvania, Texas
2025-05-14
Active, closed
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280Type 1 Diabetes, Obesity, Overweight
DrugTirzepatide
Eli Lilly and Company
Phase 3
465
California, Colorado, Florida, Iowa, Minnesota, Missouri, Nevada, North Carolina
2025-05-12
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
Arkansas, California, Florida, Georgia, Massachusetts, Michigan, Mississippi, Missouri
2025-05-08
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285Myelodysplastic Syndromes
DrugElritercept
Takeda
Phase 3
225
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Missouri, Nevada
2025-05-06
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
DrugsTAK-881·Phesgo
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
DrugZanzalintinib
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
NCT06926920Triple Negative Breast Cancer
DrugSacituzumab Govitecan
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
Active, closed
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
NCT06883240Von Willebrand Disease, Type 3
DrugsActivated Prothrombin Complex·Recombinant Factor VIIa
Hoffmann-La Roche
Observational
44
California, Minnesota, Missouri
2025-04-29
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, Ohio, Pennsylvania
2025-04-28
By invitation
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT06926621Myotonic Dystrophy Type 1 (DM1)
DrugVX-670
Vertex Pharmaceuticals Incorporated
Phase 2
44
Missouri, Virginia
2025-04-28
Recruiting
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761AML, Adult, MDS
DrugCytarabine
Stelexis BioSciences
Phase 1
125
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries
NCT06867185Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma
Checkpoint Surgical Inc.
Not applicable
60
Indiana, Missouri, Ohio, Washington
2025-04-24
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Panitumumab·Fluorouracil·Leucovorin
AbbVie
Phase 2
390
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
DrugPumitamig
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Recruiting
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038Alagille Syndrome
Ipsen
Observational
30
California, Missouri, New York, Tennessee, Texas, Utah
2025-04-22
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
DrugInfigratinib
QED Therapeutics, a BridgeBio company
Phase 2/3
24
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2025-04-22
Recruiting
Auryon Atherectomy System With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone
NCT06777901Peripheral Arterial Diseases
Angiodynamics, Inc.
Phase 4
224
Arizona, California, Louisiana, Maryland, Massachusetts, Missouri, North Carolina, Ohio
2025-04-21
Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930Lupus Erythematosus, Systemic
DrugsAZD0120·Fludarabine·Cyclophosphamide
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Active, closed
A Study of ETHIZIA Versus SURGICEL Original in Controlling Soft Tissue Bleeding During Open Surgery
NCT06664788Hemostasis, Hemostatic Techniques
Ethicon, Inc.
Not applicable
108
California, Missouri, New Jersey, New York, Texas, Utah
2025-04-16
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
DrugMRNA-1195
ModernaTX, Inc.
Phase 2
180
Massachusetts, Michigan, Missouri, Oklahoma, Texas
2025-04-16
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
NCT06858813Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
DrugLenvatinib
AbbVie
Phase 1
232
California, Illinois, Missouri, New York, Pennsylvania, Tennessee
2025-04-14
Active, closed
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
NCT06941844Major Depressive Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
Active, closed
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
NCT06891066Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugB/F/TAF
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
NCT07327489Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer
Elephas
Observational
2,000
Arkansas, Maryland, Missouri, Oklahoma, Texas
2025-04-14
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
California, Florida, Missouri, Ohio, Texas
2025-04-07
Recruiting
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
NCT05766839Hyperkalemia
DrugPatiromer
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050Graft-versus-host Disease (GVHD)
DrugsMycophenolate Mofetil·Tacrolimus·Ruxolitinib·Methotrexate
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Recruiting
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
NCT06664775Hemorrhage
Corza Medical GmbH
Phase 3
116
California, Colorado, District of Columbia, Illinois, Indiana, Kentucky, Missouri, North Carolina
2025-04-02
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York
2025-03-31
Active, closed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901Asthma
DrugAPG777
Apogee Therapeutics, Inc.
Phase 1
31
California, Illinois, Missouri, Oklahoma, Pennsylvania
2025-03-27
Recruiting
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06644781Esophageal Squamous Cell Carcinoma
DrugsIfinatamab Deruxtecan·Irinotecan·Docetaxel·Paclitaxel
Daiichi Sankyo
Phase 3
510
Arizona, California, Michigan, Minnesota, Missouri, New Jersey, New York, Pennsylvania
2025-03-27
Recruiting
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491Acute Ischemic Stroke
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022Hepatocellular Carcinoma
AstraZeneca
Phase 1/2
304
California, Maryland, Massachusetts, Missouri, New Jersey, Texas
2025-03-27
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
DrugsLetrozole·Fulvestrant
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-03-25
Recruiting
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
NCT06843317RSV Infection
DrugArexvy
Clover Biopharmaceuticals USA, LLC
Phase 1
160
Arizona, Florida, Kentucky, Missouri, Tennessee
2025-03-21
Recruiting
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
NCT06799065Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
BioPoly® Partial Resurfacing Knee Implant IDE
NCT06915363Knee Pain Chronic, Knee Osteoarthritis, Cartilage Damage, Cartilage Defects of the Knee
BioPoly LLC
Not applicable
152
Indiana, Minnesota, Missouri
2025-03-17
Recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466Menstrual Migraine
DrugRimegepant
Pfizer
Phase 3
723
Arizona, California, Florida, Georgia, Idaho, Indiana, Michigan, Missouri
2025-03-11
Recruiting
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
NCT06833073Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ
DrugIntismeran autogene
Merck Sharp & Dohme LLC
Phase 2
308
California, Colorado, Florida, Illinois, Louisiana, Missouri, Nebraska, New York
2025-03-11
Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
DrugsRapamycin·Sirolimus
Umoja Biopharma
Phase 1
106
California, Illinois, Missouri, Nebraska, Ohio, Washington
2025-03-10
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
California, Illinois, Iowa, Louisiana, Massachusetts, Missouri, North Carolina, Oregon
2025-03-10
Active, closed
A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
NCT06899802Encephalitis
Bavarian Nordic
Phase 2
411
California, Georgia, Kansas, Kentucky, Louisiana, Missouri, Nebraska, Texas
2025-03-10
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Minnesota, Missouri
2025-03-10
Recruiting
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085Hypogonadism, Male
Halozyme Therapeutics
Phase 3
100
California, Colorado, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nevada
2025-03-07
Active, closed
PREEMIE: Study for Treatment of PDA in Premature Infants
NCT06587282Patent Ductus Arteriosus (PDA)
Merit Medical Systems, Inc.
Not applicable
55
California, Florida, Georgia, Missouri, Tennessee, Texas, Wisconsin
2025-03-06
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
DrugsCisplatin/Carboplatin·MFOLFIRINOX·MFOLFOX6·Midazolam
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Recruiting
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
NCT06842355Achondroplasia
DrugTYRA-300
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Recruiting
INHANCE Stemless Reverse Shoulder IDE
NCT06323980Arthroplasty, Replacement, Shoulder
DePuy Orthopaedics
Not applicable
168
Florida, Massachusetts, Michigan, Missouri, North Carolina, Ohio, Oregon, Pennsylvania
2025-03-04
Active, closed
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
NCT06840483Breast Cancer
DrugZelenectide pevedotin
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
NCT06597006Familial Hypercholesterolemia - Homozygous
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
9
California, District of Columbia, Missouri, Utah
2025-02-28
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Maryland, Missouri, North Carolina, Pennsylvania, Virginia
2025-02-28
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949Sjögren's Syndrome
DrugDazodalibep
Amgen
Phase 3
844
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey
2025-02-25
Active, closed
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Dogwood Therapeutics Inc.
Phase 2
240
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Missouri
2025-02-21
Active, closed
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
NCT06738017Alpha 1-Antitrypsin Deficiency
BioMarin Pharmaceutical
Phase 1
6
California, Missouri, Ohio, South Carolina
2025-02-21
By invitation
A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder
NCT06878976Binge-Eating Disorder
DrugSolriamfetol
Axsome Therapeutics, Inc.
Phase 3
236
California, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri, New Jersey
2025-02-20
Active, closed
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
NCT06727565Head and Neck Squamous Cell Carcinoma
DrugsDomvanalimab·Zimberelimab·Paclitaxel·Carboplatin
Gilead Sciences
Phase 2
39
Missouri, Tennessee, Texas
2025-02-18
Active, closed
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
NCT06811909Non-infected Venous Leg Ulcer, Venous Leg Ulcer, Venous Insufficiency, Venous Stasis
BioStem Technologies
Not applicable
71
Alabama, California, Florida, Illinois, Massachusetts, Missouri, New York, Texas
2025-02-14
Active, closed
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT06834347Chronic Rhinosinusitis With Nasal Polyps
DrugsItepekimab·Mometasone furoate
Sanofi
Phase 3
231
California, Florida, Georgia, Idaho, Illinois, Indiana, Missouri, New York
2025-02-12
Recruiting
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847Neurofibromatosis Type 1
Healx Limited
Phase 2
25
Alabama, California, Colorado, District of Columbia, Illinois, Indiana, Maryland, Missouri
2025-02-10
Active, closed
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449Obesity
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
NCT06616025Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
Neuraptive Therapeutics Inc.
Phase 3
98
California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-02-10
Recruiting
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
NCT06812078Idiopathic Hypersomnia
DrugTAK-360
Takeda
Phase 2
96
California, Colorado, Florida, Missouri, North Carolina, Ohio, South Carolina, Texas
2025-02-07
Active, closed
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
NCT06678074STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
Implicit Bioscience
Phase 1/2
10
Missouri, Virginia
2025-02-06
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
DrugsPumitamig·Iza-bren·Osimertinib·Opdivo
Bristol-Myers Squibb
Phase 1/2
416
Alabama, Florida, Iowa, Missouri, New Jersey, Ohio, Oregon, Pennsylvania
2025-02-04
Active, closed
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
NCT06812325Thyroid Eye Disease (TED)
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
320
Arizona, California, Florida, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2025-02-03
By invitation
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06679881Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
170
Alabama, Arizona, Arkansas, California, Colorado, Illinois, Missouri, Nevada
2025-02-01
Recruiting
BOOM-IBD2 Pivotal Clinical Trial
NCT06571669Ulcerative Colitis, Inflammatory Bowel Diseases
Boomerang Medical
Not applicable
137
California, Kansas, Minnesota, Mississippi, Missouri, Nevada, New York, North Carolina
2025-01-31
Recruiting
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
NCT06514794T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Allotera Therapeutics
Phase 2
125
California, Colorado, District of Columbia, Florida, Georgia, Missouri, New York, Ohio
2025-01-31
Recruiting
Validity of Viome's Oral/throat Cancer Test
NCT06174428Oral and Throat Cancer, Oropharyngeal Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
Viome
Observational
1,000
Missouri, Tennessee
2025-01-27
Recruiting
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 1/2
258
Florida, Indiana, Kansas, Massachusetts, Missouri, Washington
2025-01-23
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
A Study Evaluating the Safety and Efficacy of the 3M™ V.A.C. Peel and Place Dressing
NCT06625385Wound
Solventum US LLC
Not applicable
90
Indiana, Missouri, Pennsylvania
2025-01-20
Active, closed
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420Hereditary Angioedema
Intellia Therapeutics
Phase 3
80
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio
2025-01-15
Active, closed
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463Acute Myeloid Leukemia
DrugsTagraxofusp·Venclexta·Azacitidine·Venetoclax
Stemline Therapeutics, Inc.
Phase 2
85
California, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey, New York
2025-01-14
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
DrugBGB-58067
BeOne Medicines
Phase 1
525
California, Florida, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas
2025-01-10
Recruiting
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
NCT06908356Focal Onset Seizure, Primary Generalized Epilepsy
Praxis Precision Medicines
Phase 2
50
Arizona, Florida, Maryland, Missouri, New Jersey, New York, Texas
2025-01-10
Recruiting
A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder
NCT06809179Social Anxiety Disorder
VistaGen Therapeutics, Inc.
Phase 2
60
California, Florida, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Texas
2025-01-09
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Active, closed
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059Hearing Loss
DrugDexamethasone
Cochlear
Not applicable
56
California, Colorado, Iowa, Michigan, Missouri, New York, Ohio, Oregon
2025-01-03
Active, closed
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
NCT06619509Solid Tumours
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Active, closed
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
NCT06688058Healthy
DrugNonavalent HPV vaccine
Merck Sharp & Dohme LLC
Phase 1
72
Florida, Georgia, Missouri, Tennessee
2024-12-20
Active, closed
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397HIV Infections
DrugCabotegravir
ViiV Healthcare
Phase 2
229
Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Missouri
2024-12-20
Recruiting
ViewFlex X ICE First-in-Human Study
NCT06772493Cardiac Arrhythmias
Abbott Medical Devices
Observational
500
Arkansas, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Texas
2024-12-16
Active, closed
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
NCT06733441Lymphoma
DrugZeprumetostat
Treeline Biosciences, Inc.
Phase 1
50
California, Missouri, New York, Tennessee
2024-12-16
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
NCT06747858Cystic Fibrosis, CFTR Gene Mutation
Arcturus Therapeutics, Inc.
Phase 2
33
Arizona, Arkansas, California, District of Columbia, Florida, Illinois, Massachusetts, Missouri
2024-12-12
Active, closed
The JenaValve ALIGN-AR LVAD Registry
NCT06594705Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency, Aortic Valve Disease
JenaValve Technology, Inc.
Not applicable
50
California, District of Columbia, Georgia, Illinois, Michigan, Minnesota, Missouri, New York
2024-12-09
Recruiting
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
NCT04679844Degenerative Disc Disease, Spine Fusion, Back Pain
Kuros Biosurgery AG
Not applicable
60
California, Michigan, Missouri, Pennsylvania, Tennessee, Washington
2024-12-06
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
NCT06667908Carcinoma, Non-Small-Cell Lung
DrugsJNJ-90301900·Durvalumab
Johnson & Johnson Enterprise Innovation Inc.
Phase 2
130
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New Jersey, New York
2024-12-06
Recruiting
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).
NCT06655324Healthy
Merck Sharp & Dohme LLC
Phase 1
250
California, Florida, Missouri, Nebraska, Ohio, Oklahoma, Tennessee
2024-12-05
Active, closed
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
NCT06617429Angelman Syndrome
DrugApazunersen
Ultragenyx Pharmaceutical Inc
Phase 3
129
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York
2024-12-03
Active, closed
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
NCT06706817Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Phase 3
181
California, Illinois, Massachusetts, Missouri
2024-12-03
Active, closed
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06685757Antibody-mediated Rejection
DrugFelzartamab
Biogen
Phase 3
132
California, Colorado, Illinois, Kansas, Louisiana, Minnesota, Missouri, Nebraska
2024-12-03
Recruiting
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
NCT06717698Chronic Kidney Disease
DrugSemaglutide
Novo Nordisk A/S
Phase 2
465
California, Colorado, Florida, Illinois, Indiana, Michigan, Missouri, New York
2024-12-02
Active, closed
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
NCT06669754Hereditary Angioedema (HAE)
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 3
81
Arkansas, California, Maryland, Missouri
2024-12-01
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Arizona, California, Florida, Illinois, Iowa, Kansas, Minnesota, Missouri
2024-11-27
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
DrugsTacabrutideg·Mosunetuzumab·Sonrotoclax·Glofitamab
BeOne Medicines
Phase 1/2
80
Arizona, California, Florida, Kansas, Minnesota, Missouri, New York, Pennsylvania
2024-11-27
Recruiting
CoMind Early Feasibility Study
NCT06368648Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage
CoMind Technologies Limited
Observational
581
Arizona, California, Delaware, District of Columbia, Florida, Iowa, Kansas, Missouri
2024-11-27
Recruiting
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
NCT06613100Prostate Cancer
DrugXaluritamig
Amgen
Phase 1
40
California, Missouri, Ohio, Pennsylvania, South Carolina, Washington, Wisconsin
2024-11-25
Recruiting
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
NCT06651281Crohn Disease, Colitis, Ulcerative
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06597721Advanced Solid Tumor, PDAC, HNSCC
Adcendo ApS
Phase 1
210
Arkansas, Connecticut, Massachusetts, Missouri, New York, Texas
2024-11-25
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin
Shanghai Henlius Biotech
Phase 3
550
California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada
2024-11-22
Recruiting
Acellular Dermal Matrix Investigation in Breast Reconstruction
NCT06456554Breast Reconstruction
RTI Surgical
Not applicable
467
Arkansas, California, Colorado, Kansas, Missouri, New York, Ohio, Oklahoma
2024-11-22
Recruiting
A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach
NCT06653387Carotid Artery Diseases
InspireMD
Not applicable
50
California, Indiana, Minnesota, Missouri, Montana, New York, Ohio
2024-11-20
Active, closed
Evaluation of a Simple-Prep Controlled Embolic
NCT06453642Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
Fluidx Medical Technology, Inc.
Not applicable
114
California, Colorado, Illinois, Indiana, Minnesota, Missouri, New York, North Carolina
2024-11-18
Recruiting
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
NCT06672939Obesity, Overweight
DrugOrforglipron
Eli Lilly and Company
Phase 3
150
California, Connecticut, Georgia, Illinois, Louisiana, Missouri, North Carolina, Pennsylvania
2024-11-18
Active, closed
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
NCT06616194Migraine
DrugRimegepant
Pfizer
Phase 3
200
Arizona, California, Colorado, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2024-11-15
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 1
106
California, Minnesota, Missouri, Nebraska
2024-11-11
Active, closed
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT06659640Hereditary Hemorrhagic Telangiectasia
DrugALN-6400
Alnylam Pharmaceuticals
Phase 1/2
89
Alabama, California, Florida, Indiana, Massachusetts, Minnesota, Missouri, North Carolina
2024-11-07
Recruiting
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192Breast Reconstruction
AbbVie
Phase 3
264
California, Colorado, Florida, Illinois, Maryland, Missouri, Nevada, New Jersey
2024-11-05
Active, closed
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941Hypoparathyroidism
MBX Biosciences
Phase 2
60
Florida, Georgia, Mississippi, Missouri, Nevada, New York, Ohio, Texas
2024-10-31
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
DrugsBBO-10203·Ribociclib·Folfox·Fulvestrant
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
California, Florida, Indiana, Massachusetts, Missouri, New York, Tennessee, Texas
2024-10-29
Recruiting
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT06343805Primary Myelofibrosis
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
California, Florida, Kansas, Massachusetts, Michigan, Missouri, New York, North Carolina
2024-10-23
Active, closed
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Chronic Graft-versus-host-disease
DrugsAxatilimab·Ruxolitinib·Methylprednisolone·Prednisolone
Incyte Corporation
Phase 2
130
Arizona, California, Colorado, Connecticut, Florida, Illinois, Maryland, Missouri
2024-10-11
Active, closed
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
NCT06361836Hidradenitis Suppurativa
DrugSBT777101
Sonoma Biotherapeutics, Inc.
Phase 1
24
Massachusetts, Minnesota, Missouri, New York, North Carolina, Texas
2024-10-09
Recruiting
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955Acute Respiratory Distress Syndrome, Infections
BioAegis Therapeutics Inc.
Phase 2
600
California, Georgia, Illinois, Kentucky, Minnesota, Missouri, Nebraska, New York
2024-10-03
Active, closed
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
NCT06473779Severe Asthma
AstraZeneca
Phase 3
326
California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Oklahoma, Texas
2024-09-30
Active, closed
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258Alzheimer's Disease
DrugsE2814·Lecanemab
Eisai Inc.
Phase 2
105
Arizona, Connecticut, Florida, Georgia, Mississippi, Missouri, Pennsylvania, Tennessee
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Arizona, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, North Carolina
2024-09-30
Active, closed
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
NCT06564194Respiratory Syncytial Virus (RSV), Infectious Disease
Immorna Biotherapeutics, Inc.
Phase 1
75
Florida, Louisiana, Missouri
2024-09-25
Active, closed
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
151
California, Colorado, Connecticut, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2024-09-18
Active, closed
Safety and Effectiveness of Cochlear Implantation in an Expanded Adult Population
NCT06293482Hearing Loss, Sensorineural, Hearing Loss, Bilateral
Cochlear
Not applicable
50
Arizona, California, Florida, Indiana, Missouri, New York, Ohio, Pennsylvania
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
DrugBelimumab
GlaxoSmithKline
Phase 3
440
California, Florida, Missouri, New York, North Carolina, Pennsylvania, Texas, Utah
2024-09-11
Active, closed
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751Tourette Syndrome
Noema Pharma AG
Phase 2
164
Arizona, California, Florida, Georgia, Massachusetts, Michigan, Missouri, Nebraska
2024-09-10
Active, closed
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
NCT06606106Overweight, Obesity
DrugBrenipatide
Eli Lilly and Company
Phase 1
302
California, Florida, Missouri, Texas
2024-09-05
Active, closed
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685Peripheral Arterial Disease (PAD)
Amplitude Vascular Systems, Inc.
Not applicable
115
Arkansas, California, Colorado, Georgia, Iowa, Missouri, New Jersey, New York
2024-09-05
Active, closed
The SpeedPlate™ Rapid Compression Implant Study (The SPRINT™ Study)
NCT06548581Joint Arthrodesis, Joint Fixation
Treace Medical Concepts, Inc.
Observational
92
Alabama, Florida, Missouri, Ohio, Texas
2024-09-04
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-09-03
Not yet open
Preterm Infants Fed a Human Milk Fortifier
NCT05551975Growth
Abbott Nutrition
Not applicable
321
Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York
2024-09
Recruiting
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
NCT06343792Steroid Refractory GVHD
DrugRLS-0071
ReAlta Life Sciences, Inc.
Phase 2
66
California, Georgia, Missouri, Ohio
2024-08-31
Recruiting
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
NCT06193889Myasthenia Gravis, Generalized Myasthenia Gravis
DrugsKYV-101·Fludarabine·Cyclophosphamide
Kyverna Therapeutics
Phase 2/3
66
California, Florida, Indiana, Missouri, Oregon, Pennsylvania, Texas, Utah
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Arizona, California, Florida, Idaho, Kansas, Michigan, Missouri, North Carolina
2024-08-28
Active, closed
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
NCT06625398Thyroid Eye Disease
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
204
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-08-27
Active, closed
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411Thyroid Eye Disease
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
132
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-08-27
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Alabama, Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New Jersey
2024-08-26
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
Abbott Structural Heart Device Registry
NCT06590467Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale
Abbott Medical Devices
Observational
2,500
California, District of Columbia, Florida, Missouri, New Jersey, New York, Ohio, Pennsylvania
2024-08-21
Active, closed
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed
NCT06544733HIV-1-Infection
DrugB/F/TAF
Gilead Sciences
Phase 2/3
675
Alabama, California, District of Columbia, Florida, Georgia, Michigan, Missouri, New Jersey
2024-08-20
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Active, closed
CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin
NCT06601166Type 2 Diabetes
DexCom, Inc.
Not applicable
283
Colorado, Florida, Georgia, Indiana, Minnesota, Missouri, New York, North Carolina
2024-08-15
Recruiting
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer
DrugOlaparib
MOMA Therapeutics
Phase 1
220
Arizona, California, Florida, Missouri, New York, Pennsylvania, South Carolina, Tennessee
2024-08-13
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Eribulin·Vinorelbine·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Arizona, California, Colorado, District of Columbia, Florida, Massachusetts, Minnesota, Missouri
2024-08-13
Recruiting
Study of XB010 in Subjects With Solid Tumors
NCT06545331Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
DrugPembrolizumab
Exelixis
Phase 1
396
California, District of Columbia, Florida, Georgia, Illinois, Missouri, New York, North Carolina
2024-08-06
Recruiting
A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)
NCT06072430Septic Shock, Sepsis, Hypovolemia
Vivacelle Bio
Phase 3
46
Arizona, Georgia, Missouri, Nebraska, North Carolina, Oregon
2024-08-06
Recruiting
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
NCT06549465PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics
Phase 2
93
California, Massachusetts, Missouri, Nebraska, New York, North Carolina, Ohio
2024-08-06
Active, closed
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
NCT06449209Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
DrugsPumitamig·Topotecan·Etoposide·Paclitaxel
BioNTech SE
Phase 2
110
Alaska, California, Florida, Illinois, Indiana, Kentucky, Minnesota, Missouri
2024-08-05
By invitation
Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
NCT06544798Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
MeiraGTx, LLC
Phase 2
276
Arizona, Florida, Iowa, Missouri, New York, North Carolina, Pennsylvania
2024-08-02
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301Metastatic Non-small Cell Lung Cancer
DrugPembrolizumab
NovoCure GmbH
Phase 3
734
Alabama, Arizona, California, Florida, Illinois, Indiana, Kansas, Missouri
2024-07-31
Recruiting
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
NCT06226805Acute Ischemic Stroke
Basking Biosciences, Inc.
Phase 2
228
Arizona, California, Florida, Michigan, Missouri, New Jersey, North Carolina, Ohio
2024-07-31
Active, closed
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
NCT06565650Dry Eye
Bausch & Lomb Incorporated
Phase 4
216
California, Florida, Georgia, Indiana, Missouri, North Carolina, Tennessee
2024-07-31
Recruiting
Investigations of Reproductive Cancers in Women
NCT06527157Uterine Cancer
PinkDx, Inc.
Observational
4,500
Alabama, California, Florida, Illinois, Indiana, Minnesota, Missouri, New York
2024-07-30
Active, closed
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
DrugsMIRV·Mirvetuximab Soravtansine
AbbVie
Phase 2
108
California, Kentucky, Maryland, Missouri, Nevada, New Jersey, New York, North Carolina
2024-07-29
Recruiting
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
NCT06560307Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Enterra Medical, Inc.
Not applicable
50
Florida, Kentucky, Michigan, Missouri, Oregon, Washington
2024-07-25
Recruiting
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
NCT06386146Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
144
Colorado, Florida, Missouri, Ohio, Tennessee, Texas
2024-07-24
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
Angiex, Inc.
Phase 1
80
California, Florida, Missouri, Tennessee, Texas, Virginia
2024-07-22
Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
NCT06979323Asthma
DrugDepemokimab
GlaxoSmithKline
Phase 3
150
Florida, Kansas, Missouri, New Jersey, New York, Pennsylvania, Texas
2024-07-19
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
NCT06521554Locally Advanced Solid Tumor, Metastatic Solid Tumor
Nuvalent Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Maryland, Massachusetts, Michigan, Missouri
2024-07-18
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883Inflammatory Bowel Diseases, Crohn's Disease
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
California, Colorado, Florida, Georgia, Louisiana, Missouri, Nevada, North Carolina
2024-07-18
Rows per page Showing 1–500 of 990
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/missouri

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 990 of those studies with a site in Missouri.

How many clinical trials are recruiting in Missouri?

517 of the 990 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 21 have not yet opened recruitment, 409 are active but closed to new participants, and 43 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Missouri), 990 studies
PhaseStudiesRecruitingShare
Phase 323810924%
Phase 221611021.8%
Phase 11609216.2%
Phase 1/21307913.1%
Not applicable1034710.4%
Observational94509.5%
Phase 2/333203.3%
Phase 415101.5%
Phase EARLY_PHASE1100.1%

Most active sponsors

Lead sponsors with the most studies (Missouri)
Lead sponsorStudiesRecruiting
AstraZeneca4521
Merck Sharp & Dohme LLC3623
AbbVie2012
Pfizer208
Novartis Pharmaceuticals1814
Eli Lilly and Company178
Hoffmann-La Roche174
Janssen Research & Development, LLC175
GlaxoSmithKline169
Gilead Sciences146
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.